Latest article: The Gut-lung Axis: Reducing URTIs through microbiome support

Upper respiratory tract infections (URTIs) remain one of the most common reasons for primary care visits globally, contributing significantly to healthcare burden, absenteeism, and reduced quality of life across both paediatric and adult populations.⁹ Despite their typically self-limiting nature, URTIs drive substantial antibiotic prescribing, often unnecessarily, further compounding antimicrobial resistance and disrupting host microbial ecology.¹⁰

Emerging evidence reframes URTIs not simply as localised respiratory events, but as manifestations of systemic immune function. Central to this is the gut microbiome, now recognised as a key regulator of immune resilience through its interaction with the respiratory tract, a concept described as the gut lung axis.⁴ This bidirectional communication network links intestinal microbial activity with pulmonary immune responses (Figure 1), influencing susceptibility, severity, and recovery from respiratory infections.^11,12

Research indicates that a diverse ecosystem of healthy bacteria produces essential metabolites, such as short-chain fatty acids (SCFAs) and desaminotyrosine, which prime pulmonary immunity and enhance the activity of interferons and immune cells.^13,4 Conversely, viral lung infections can trigger dysbiosis, a state of microbial imbalance often caused by systemic inflammation, reduced appetite, or decreased oxygen levels. This disruption of the digestive environment can compromise the epithelial barrier, leading to gastrointestinal distress and increased vulnerability to secondary bacterial infections in both the gut and the lungs.¹³ Understanding and targeting this axis offers clinicians a novel, evidence-based approach to reducing URTI burden through microbiome directed strategies.